tabletki powlekane
Sponsors
National Institute Of Cardiology, KRKA tovarna zdravil d.d. Novo mesto, Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy, Medical University Of Gdansk, Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
Conditions
000 people may be affected by HCM3) and all-cause mortality (RR 2.5; 95% CI 1.8-3.4) with a mean follow-up of 7 years.
HenceAF occurence is even higherAcute Coronary Syndrom (ACS)Chronic obstructive pulmonary disease (COPD)Compulsive Sexual Behaviour DisorderCoronary Artery DiseaseCoronary Atherosclerosis
Phase 2
Randomized, double-blind, multicenter, parallel group, placebo-controlled study to evaluate the efficacy and safety of phenofibrate treatment on the functions of beta cells in children and adolescents with newly diagnosed of type 1 diabetes
RecruitingCTIS2024-517483-34-00
Start: 2022-09-21Target: 98Updated: 2025-06-10
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of tianeptine in the treatment of covid fog symptoms in patients after COVID-19 with the study of the pathophysiology of the phenomenon using positron emission tomography, biochemical, immunological and electrophysiological parameters (COVMENT).
Not yet recruitingCTIS2024-510790-19-00
Target: 140Updated: 2024-12-02
A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of iN1011-N17-02 in Patients with Post herpetic Neuralgia (PHN)
CompletedCTIS2024-518747-38-00
End: 2025-09-01Target: 66Updated: 2025-07-14
Efficacy and safety of a combined therapy with Alpha-Lipoic Acid and Benfotiamine in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, controlled, parallel group, double-blind, double-dummy 3-arm trial
Not yet recruitingCTIS2025-521985-82-00
Target: 136Updated: 2026-02-18
Phase 3
The assessment of cysteinyl leukotriene receptor antagonist role in inhibition of atherosclerosis, proliferation and its influence on endothelial function in patients undergoing endovascular treatment due to peripheral arterial disease.
Active, not recruitingCTIS2024-511894-32-00
Start: 2021-08-19Target: 200Updated: 2024-07-01
The use of sildenafil in patients with univentricular heart after Fontan operation - a pilot SINFON-POL study.
RecruitingCTIS2023-503913-31-01
Start: 2025-06-27Target: 60Updated: 2025-07-22
Pharmacological treatment of compulsive sexual behaviour disorder
WithdrawnCTIS2024-514490-22-00
Target: 410Updated: 2024-09-30
Evaluation of safety and efficacy of two ticagrelorbased de-escalation antiplatelet strategies in acute coronary syndrome: the randomized, multicenter, double-blind ELECTRA RCT study.
Active, not recruitingCTIS2024-518090-34-00
Start: 2022-02-07Target: 4500Updated: 2024-11-24
FORMA – a multicentre randomized-controlled trial to evaluate the efficacy and safety of ketoanalogues of essential amino acids in prophylaxis of protein-energy wasting in nephrotic syndrome.
RecruitingCTIS2024-517880-22-00
Start: 2023-01-04Target: 150Updated: 2026-01-09
Non-commercial clinical trial of statins CAncer preventive and Pleiotropic TherApy IN smokers with chronic obstructive pulmonary disease (COPD)
Clinical part: Atorvastatin effect on reduction of COPD exacerbations.
Genomic part: Assessment of immunobiology of COPD related lung carcinoma and inflammatory pathways activation based on gene expression profiles of the peripheral blood leukocytes (PBLs) and peripheral blood mononuclear cells (PBMCs) from smokers with chronic obstructive pulmonary disease (COPD).
RecruitingCTIS2024-516714-37-00
Start: 2022-01-19Target: 480Updated: 2024-12-02
The effect of sertraline on anxiety-depressive symptoms, endothelial dysfunction and biomarkers in heart failure patients with preserved ejection fraction
CompletedCTIS2024-515061-33-00
Start: 2024-03-22End: 2025-12-05Target: 485Updated: 2025-07-24
Optimal medical treatment of uncontrolled hypertension. OPTIMAL-HT
RecruitingCTIS2024-517628-20-00
Start: 2023-10-24Target: 2500Updated: 2025-04-29
The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement
RecruitingCTIS2023-509111-89-00
Start: 2025-10-15Target: 66Updated: 2025-06-30
Phase 4
Early ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy
CompletedCTIS2023-508743-43-00
End: 2025-09-16Target: 725Updated: 2024-09-16
A multiarm, randomized, open label Clinical study comparing AntiatheroSClerotic efficacy of selected Antidiabetic agents in patients with coronary artery disease and preDiabetES. A randomised clinical trial (CASCADES)
RecruitingCTIS2023-508525-27-00
Start: 2025-07-10Target: 300Updated: 2025-08-27
The effects of 2-week long treatment with naproxen sodium (Nalgesin® Forte) on synovial fluid cytokine and naproxen concentration and clinical outcomes in patients with knee osteoarthritis – ZOOM-IN: A randomized, double-blind, placebo-controlled, parallel, multicenter clinical trial
CompletedCTIS2023-505875-56-00
Start: 2025-05-21End: 2025-09-17Target: 38Updated: 2025-10-21
A multicenter, prospective clinical TRrial evaluating patient’s ability to make an independent and safe decision regarding the USe of the medicinal product Sildenafil Polpharma100 mg indicated in the Treatment of erectile dysfunction.
TRUST Trial on Responsible Use and Self-assessed Treatment.
Not yet recruitingCTIS2025-522923-81-00
Target: 200Updated: 2026-01-26